Screener
MapLight Therapeutics, Inc. MPLT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $53.68M+171% | $64.62M+212% | $27.09M+61.1% | $26.85M— | $19.79M— | ||
| $10.82M+188% | $18.75M+809% | $4.4M+7.9% | $3.82M— | $3.76M— | ||
| $64.5M+174% | $83.38M+266% | $31.5M+50.8% | $30.67M— | $23.54M— | ||
| -$64.5M-174% | -$83.38M-266% | -$31.5M-50.8% | -$30.67M— | -$23.54M— | ||
| $1.36M+248% | $3.83M+147% | $2.08M+10.8% | $1.63M— | $392K— | ||
| -$60.67M-172% | -$79.55M-275% | -$29.42M-54.7% | -$29.85M-62.2% | -$22.34M-18.0% | ||
| -$1.34+95.4% | —— | -$37.18-48.2% | —— | -$29.33— | ||
| -$64.34M-175% | -$83.24M-269% | -$31.4M-51.7% | -$30.49M— | -$23.38M— | ||
| -$64.5M-174% | -$83.38M-266% | -$31.5M-50.8% | -$30.67M— | -$23.54M— |
FAQ
- Is MapLight Therapeutics, Inc. profitable?
- MapLight Therapeutics, Inc. is not currently profitable: it reported a net loss of $199.5M over the trailing twelve months.
- What is MapLight Therapeutics, Inc.'s earnings per share?
- MapLight Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-95.86.
- Where does MapLight Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from MapLight Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.